GO:1901862 negative regulation of muscle tissue development: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901862 (negative regulation of muscle tissue development) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of muscle tissue development.
• Myostatin (MSTN) is the best-characterized negative regulator of skeletal muscle mass; its genetic deletion causes dramatic muscle hyperplasia and hypertrophy in mice.
• The TGF-beta superfamily, including myostatin, activins, and BMPs, provides the principal extracellular brake on muscle growth and differentiation.
• Cancer cachexia and sarcopenia both involve excessive activation of negative regulatory pathways that suppress muscle tissue development and accelerate atrophy.
• MicroRNAs and exercise-responsive signaling pathways fine-tune the balance between muscle growth and inhibition, making them attractive therapeutic targets.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting causal roles of negative regulators in muscle biology.
Description
Muscle tissue development is a tightly orchestrated process that builds and maintains skeletal, cardiac, and smooth muscle throughout embryonic development and adult life. Equally important is the ability to restrain this process: negative regulation of muscle tissue development (GO:1901862) encompasses all molecular events that stop, prevent, or reduce the frequency, rate, or extent of muscle tissue formation. This GO term is critical for understanding how organisms balance growth with energy expenditure, and how dysregulation contributes to diseases such as cachexia, sarcopenia, and cardiac hypertrophy. The most extensively studied negative regulator is myostatin (MSTN), a TGF-beta superfamily member that acts as a potent inhibitor of skeletal muscle growth. Beyond myostatin, a network of signaling molecules, transcription factors, and microRNAs converges to suppress muscle development under specific physiological or pathological conditions. Understanding these mechanisms has direct clinical relevance: blocking negative regulation can ameliorate muscle wasting, while excessive inhibition contributes to metabolic and cardiovascular disorders. This article integrates authoritative QuickGO annotation for GO:1901862 with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental models used to study negative regulation of muscle tissue development.
negative regulation of muscle tissue development At A Glance
| GO ID | GO:1901862 |
|---|---|
| GO term | negative regulation of muscle tissue development |
| Ontology | biological_process |
| Synonym | down regulation of muscle tissue development; down-regulation of muscle tissue development; downregulation of muscle tissue development; inhibition of muscle tissue development |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of muscle tissue development |
| Related biological process | Muscle tissue development (GO:0060537); regulation of muscle tissue development (GO:1901861) |
| Key negative regulators | Myostatin (MSTN), TGF-beta superfamily ligands, activins, BMPs, and downstream Smad signaling |
| Physiological contexts | Embryonic muscle patterning, adult muscle homeostasis, response to injury, aging, and metabolic stress |
| Pathological contexts | Cancer cachexia, sarcopenia, cardiac hypertrophy, and muscle degenerative disorders |
What Is GO:1901862?
GO:1901862, negative regulation of muscle tissue development, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of muscle tissue development. In practical terms, it includes signaling cascades, transcriptional programs, and post-transcriptional controls that put the brakes on the formation, growth, or maturation of muscle tissue. This term is a biological_process and is distinct from positive regulation or regulation of muscle tissue development. Synonyms include down regulation of muscle tissue development, down-regulation of muscle tissue development, downregulation of muscle tissue development, and inhibition of muscle tissue development.
Why Is negative regulation of muscle tissue development Important in Cell Biology?
Negative regulation of muscle tissue development is fundamental to organismal health because it prevents excessive muscle growth that would otherwise impose unsustainable metabolic and mechanical demands. At the same time, pathological overactivation of these inhibitory pathways drives muscle wasting in cancer cachexia and sarcopenia, conditions that reduce quality of life and increase mortality. Understanding the molecular players that execute GO:1901862 provides a rational basis for therapeutic strategies aimed at preserving or restoring muscle mass in diverse clinical settings.
• Maintains metabolic homeostasis by limiting energetically expensive muscle overgrowth.
• Myostatin knockout mice exhibit dramatic muscle hyperplasia, proving that negative regulation is a dominant brake on muscle mass.
• Cancer cachexia is defined in part by involuntary muscle loss, often driven by excessive negative regulatory signaling.
• Sarcopenia, the age-related loss of muscle mass and function, involves imbalanced negative regulation and can be mitigated by exercise and protein intake.
• Cardiac hypertrophy involves pathological activation of negative regulators that contribute to heart failure.
• MicroRNAs provide a layer of post-transcriptional negative regulation that fine-tunes muscle development.
• Exercise and protein metabolism interact with negative regulatory pathways to determine net muscle growth.
• The TGF-beta superfamily, including myostatin, is a major source of negative regulatory signals in muscle.
• Targeting negative regulators with CRISPR models enables causal testing of their roles in muscle disease.
• Understanding GO:1901862 informs development of biologics and small molecules to treat muscle-wasting conditions.
What Happens During negative regulation of muscle tissue development?
Initiation by extracellular inhibitory ligands
In simple terms: The process often begins when signaling molecules outside the muscle cell tell it to slow down or stop growing.
Negative regulation of muscle tissue development is frequently initiated by secreted ligands of the TGF-beta superfamily, most notably myostatin (MSTN). Myostatin is produced primarily in skeletal muscle and acts as a negative autocrine/paracrine regulator; its binding to activin type II receptors triggers intracellular signaling that suppresses muscle growth. Other TGF-beta family members, including activins and bone morphogenetic proteins (BMPs), can also inhibit myogenic differentiation depending on context. These extracellular cues represent the first layer of negative control over muscle tissue development.
Intracellular Smad-dependent signaling
In simple terms: Once the stop signal reaches the cell, a relay system inside the cell carries the message to the nucleus.
Upon ligand binding, activin type II receptors phosphorylate type I receptors, which then activate Smad2/3 transcription factors. Phosphorylated Smad2/3 forms complexes with Smad4 that translocate to the nucleus and regulate target gene expression, ultimately inhibiting myogenic regulatory factors such as MyoD and myogenin. This Smad-dependent pathway is a central mechanism through which negative regulation of muscle tissue development is executed at the transcriptional level.
Transcriptional repression of myogenic programs
In simple terms: Inside the nucleus, the stop signal turns off genes that would otherwise build muscle.
Activated Smad complexes and other inhibitory transcription factors suppress the expression of key myogenic regulatory factors (MRFs) including MyoD, Myf5, myogenin, and MRF4. This transcriptional repression reduces the ability of satellite cells and myoblasts to proliferate and differentiate, thereby decreasing the rate of muscle tissue development. Negative regulation at this stage can also involve histone modifications and chromatin remodeling that silence muscle-specific enhancers.
Post-transcriptional and microRNA-mediated control
In simple terms: Small RNA molecules can put additional brakes on muscle-building instructions after they are copied from DNA.
MicroRNAs (miRNAs) provide a post-transcriptional layer of negative regulation of muscle tissue development. Specific miRNAs can target mRNAs encoding myogenic factors or components of the IGF-1/Akt/mTOR pathway, reducing their translation or promoting their degradation. For example, miR-1, miR-133, and miR-206 are dynamically regulated during muscle development and can either promote or inhibit differentiation depending on context. This miRNA network allows rapid, reversible fine-tuning of muscle growth in response to physiological demands.
Integration with protein metabolism and atrophy pathways
In simple terms: The stop signal also shifts the balance so that muscle protein is broken down faster than it is built.
Negative regulation of muscle tissue development is closely linked to pathways controlling protein synthesis and degradation. Activation of myostatin signaling can inhibit Akt/mTOR-mediated protein synthesis and upregulate ubiquitin-proteasome components such as MuRF1 and atrogin-1, promoting muscle atrophy. Exercise and adequate protein intake can counteract these catabolic signals by stimulating mTOR and suppressing negative regulators. Thus, GO:1901862 encompasses not only developmental inhibition but also metabolic shifts that reduce net muscle mass.
Key Genes Involved in GO:1901862 negative regulation of muscle tissue development
The following genes and proteins are established participants in negative regulation of muscle tissue development, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta superfamily ligand that inhibits skeletal muscle growth | Knockout causes muscle hyperplasia; major target for cachexia and sarcopenia |
| ACVR2B | Activin type IIB receptor that mediates myostatin signaling | Dominant negative receptor blocks myostatin and increases muscle mass |
| SMAD2 | Receptor-regulated Smad that transduces TGF-beta/myostatin signals | Phosphorylation status reflects negative regulatory activity |
| SMAD3 | Receptor-regulated Smad that cooperates with SMAD2 to repress myogenic genes | Genetic deletion or knockdown can relieve inhibition of myogenesis |
| SMAD4 | Common Smad required for nuclear translocation of SMAD2/3 complexes | Essential for canonical TGF-beta signaling in muscle |
| MYOD1 | Myogenic regulatory factor whose suppression reduces muscle differentiation | Readout of negative regulation; target of Smad-mediated repression |
| MYOG | Myogenin, a MRF required for terminal differentiation | Downregulated by negative regulators; marker of differentiation block |
| MEF2C | Transcription factor cooperating with MRFs; inhibited by negative signals | Integrates calcium and TGF-beta signals in muscle |
| FOXO1 | Forkhead transcription factor that promotes atrophy gene expression | Activated when negative regulation dominates; links to proteolysis |
| FOXO3 | Forkhead transcription factor inducing MuRF1 and atrogin-1 | Mediates muscle wasting downstream of negative regulators |
| TRIM63 | MuRF1 E3 ubiquitin ligase that targets sarcomeric proteins for degradation | Upregulated during negative regulation; marker of atrophy |
| FBXO32 | Atrogin-1 E3 ubiquitin ligase involved in muscle protein breakdown | Transcriptional target of FOXO; increases with negative regulation |
| MIR1-1 | MicroRNA that can inhibit myoblast differentiation | Post-transcriptional negative regulator; context-dependent |
| MIR133A | MicroRNA that regulates myoblast proliferation and differentiation | Bidirectional modulator of muscle development |
| MIR206 | Muscle-specific microRNA involved in differentiation | Potential negative or positive regulator depending on targets |
| IGF1 | Growth factor that promotes muscle growth; opposed by negative regulators | Counteracts myostatin and FOXO signaling |
| AKT1 | Kinase that stimulates protein synthesis; inhibited by negative regulation | Central node integrating growth and inhibitory signals |
How Is negative regulation of muscle tissue development Regulated?
Negative regulation of muscle tissue development is itself regulated at multiple levels. Extracellularly, myostatin bioavailability is controlled by binding proteins such as follistatin and by proteolytic processing. Intracellularly, the Smad pathway is modulated by inhibitory Smads (Smad6/7) and by cross-talk with MAPK and PI3K/Akt signaling. Exercise and nutritional status strongly influence these pathways: resistance exercise and adequate protein intake stimulate mTOR and suppress FOXO-mediated atrophy, thereby reducing negative regulation. MicroRNAs add another layer of control by targeting mRNAs encoding both positive and negative regulators. In pathological states such as cancer cachexia, systemic inflammation and tumor-derived factors can override normal homeostatic control, leading to sustained activation of negative regulatory programs.
negative regulation of muscle tissue development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Cancer cachexia; sarcopenia; muscle hypertrophy | MSTN knockout mouse; overexpression in C2C12 myotubes |
| ACVR2B | Muscle wasting; cachexia | Dominant-negative ACVR2B knock-in mouse |
| FOXO1 | Sarcopenia; cancer cachexia | FOXO1 knockout or point-mutant (constitutively active) mouse |
| TRIM63 | Muscle atrophy; cachexia | TRIM63 knockout mouse; overexpression in muscle cells |
| MIR1-1 | Muscle development; regeneration | miR-1 knockout or transgenic overexpression in zebrafish/mouse |
Cancer cachexia
Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support. Excessive negative regulation of muscle tissue development, driven by tumor-derived factors and systemic inflammation, contributes to muscle wasting. Myostatin and activin signaling are often elevated in cachectic patients, and blocking these pathways is an active therapeutic strategy. Understanding GO:1901862 provides a mechanistic framework for cachexia research.
Sarcopenia
Sarcopenia is the age-related loss of muscle mass and strength, which increases falls, disability, and mortality. Aging is associated with impaired muscle protein synthesis and a shift toward catabolic signaling, including increased myostatin and FOXO activity. Strategies to prevent sarcopenia, such as resistance exercise and adequate protein intake, work in part by suppressing negative regulatory pathways. Thus, GO:1901862 is directly relevant to geriatric muscle health.
Cardiac hypertrophy and heart failure
Pathological cardiac hypertrophy involves activation of fetal gene programs and negative regulators that initially compensate but eventually contribute to heart failure. While myostatin is best known in skeletal muscle, TGF-beta superfamily signaling also modulates cardiac muscle development and remodeling. Dysregulation of negative regulatory processes can lead to maladaptive hypertrophy and fibrosis. Studying GO:1901862 in cardiac context helps dissect these mechanisms.
Muscle degenerative disorders
In conditions such as muscular dystrophies, chronic negative regulation of muscle tissue development and regeneration exacerbates weakness. Elevated myostatin signaling has been observed in some dystrophic models, and inhibition of myostatin improves muscle mass in preclinical studies. However, the balance between preventing excessive growth and promoting repair is delicate. CRISPR models targeting negative regulators are valuable for testing therapeutic hypotheses.
From negative regulation of muscle tissue development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MSTN increase muscle mass? | MSTN knockout mouse or CRISPR knockout in C2C12 cells |
| Does a point mutation in ACVR2B block myostatin signaling? | ACVR2B point-mutation knock-in mouse or cells |
| Can overexpression of FOXO1 induce atrophy? | FOXO1 overexpression in mouse muscle or myotubes |
| What is the role of miR-1 in muscle development? | miR-1 knockout or tagged knock-in in zebrafish/mouse |
| Does Smad3 mediate myostatin-induced inhibition? | SMAD3 knockout or point-mutant (phospho-deficient) cells |
| Can CRISPR activation of IGF1 counteract negative regulation? | CRISPRa overexpression of IGF1 in muscle cells |
How to Study the negative regulation of muscle tissue development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript abundance | Identify genes suppressed by myostatin |
| Phosphoproteomics | Phosphorylation of Smad2/3 and other kinases | Map signaling downstream of TGF-beta |
| Western blot | Protein levels of myogenic factors and atrophy markers | Validate knockout or overexpression |
| Immunofluorescence | Myotube size, fusion index, fiber type | Assess differentiation in vitro |
| Histology (H&E) | Muscle fiber cross-sectional area | Quantify hypertrophy in knockout mice |
| Grip strength test | In vivo muscle function | Evaluate sarcopenia interventions |
| miRNA qPCR | Expression of microRNAs | Study post-transcriptional regulation |
| CRISPR screening | Phenotypic effects of gene knockout | Identify novel negative regulators |
Transcriptomic profiling (RNA-seq)
RNA sequencing measures global gene expression changes during negative regulation of muscle tissue development. It can identify myogenic regulatory factors (MYOD1, MYOG) and atrophy genes (TRIM63, FBXO32) that are suppressed or induced by inhibitory signals. Comparing wild-type and CRISPR knockout models reveals direct and indirect targets of negative regulators.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics quantifies protein abundance and post-translational modifications, such as Smad2/3 phosphorylation, that reflect active negative regulatory signaling. It can also measure sarcomeric protein degradation products in atrophy models. Phosphoproteomics is particularly useful for mapping kinase cascades downstream of myostatin.
Imaging and histology
Immunofluorescence and histochemistry visualize muscle fiber size, type, and myonuclear number. Myostatin knockout mice show dramatic fiber hyperplasia and hypertrophy by histology. Live-cell imaging of fluorescently tagged myogenic factors can track differentiation dynamics in vitro.
Functional assays for muscle growth
In vitro myoblast differentiation assays (e.g., C2C12 cells) measure fusion index and myotube diameter under inhibitory conditions. In vivo, grip strength, treadmill endurance, and muscle wet weight assess functional outcomes of manipulating negative regulators. These assays bridge molecular mechanisms to physiological relevance.
How CRISPR Can Be Used to Study GO:1901862 negative regulation of muscle tissue development
Knockout
CRISPR knockout of negative regulators such as MSTN or SMAD3 in cell lines or animal models can relieve inhibition of muscle tissue development, leading to increased myotube formation or muscle mass. Knockout studies provide causal evidence for the role of specific genes in GO:1901862. Pooled CRISPR screens can identify novel negative regulators in an unbiased manner.
Point Mutation
Point mutations can be introduced to dissect specific phosphorylation sites or ligand-binding residues. For example, mutating the phospho-acceptor sites in SMAD3 can prevent its activation, thereby blocking negative regulation. Point-mutation knock-in models are valuable for studying subtle functional changes without altering protein levels.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) into endogenous loci allows real-time monitoring of negative regulator expression. Tagged knock-in of MSTN or FOXO1 enables tracking of protein localization and stability. Knock-in of disease-associated mutations can model human conditions affecting muscle development.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of negative regulators such as myostatin or FOXO1 can induce muscle atrophy or block differentiation. Overexpression models are useful for testing whether a candidate gene is sufficient to inhibit muscle tissue development. They complement loss-of-function approaches.
How EDITGENE Supports negative regulation of muscle tissue development Research
Researchers studying negative regulation of muscle tissue development-related genes often need to determine whether a candidate gene is causally involved in suppressing muscle growth or differentiation. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes within GO:1901862.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of muscle tissue development research.
Frequently Asked Questions About negative regulation of muscle tissue development
What is GO:1901862?
GO:1901862 is the Gene Ontology term for negative regulation of muscle tissue development, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of muscle tissue development.
What genes are involved in negative regulation of muscle tissue development?
Key genes include MSTN (myostatin), ACVR2B, SMAD2/3/4, FOXO1/3, TRIM63, FBXO32, and several microRNAs such as miR-1 and miR-133.
How does myostatin inhibit muscle growth?
Myostatin binds activin type II receptors, activating Smad2/3 signaling that represses myogenic regulatory factors and promotes protein degradation, thereby reducing muscle mass.
What diseases are linked to negative regulation of muscle tissue development?
Cancer cachexia, sarcopenia, cardiac hypertrophy, and muscular dystrophies all involve dysregulated negative regulation of muscle tissue development.
Can CRISPR be used to study negative regulation of muscle tissue development?
Yes, CRISPR knockout, knock-in, and overexpression models allow causal testing of genes such as MSTN and SMAD3 in muscle cells and animal models.
What is the role of microRNAs in negative regulation of muscle tissue development?
MicroRNAs such as miR-1, miR-133, and miR-206 post-transcriptionally modulate myogenic factors and signaling pathways, providing fine-tuning of muscle growth.
How is negative regulation of muscle tissue development measured experimentally?
Common methods include RNA-seq, Western blot for Smad phosphorylation, immunofluorescence for myotube size, and functional tests like grip strength.
What is the difference between negative regulation and positive regulation of muscle tissue development?
Negative regulation suppresses muscle formation, while positive regulation promotes it; both are essential for balanced muscle homeostasis.
Which signaling pathways mediate negative regulation of muscle tissue development?
The TGF-beta superfamily pathway, including myostatin-Smad signaling, and the FOXO-mediated atrophy pathway are central mediators.
How can EDITGENE help study negative regulation of muscle tissue development?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to muscle biology research.
Conclusion
Negative regulation of muscle tissue development (GO:1901862) is a fundamental biological process that restrains muscle growth and maintains metabolic balance. Its dysregulation underlies major clinical conditions including cancer cachexia, sarcopenia, and cardiac hypertrophy. The TGF-beta superfamily, led by myostatin, and downstream Smad and FOXO pathways constitute the core machinery. MicroRNAs add an additional layer of control. CRISPR-based models are indispensable for dissecting these mechanisms and for developing targeted therapies. EDITGENE provides comprehensive CRISPR services to support research on GO:1901862 and related muscle biology.
References
- 1. Fearon K et al.. 2011. Definition and classification of cancer cachexia: an international consensus.. Lancet Oncol 12(5):489-95 PMID: 21296615
- 2. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 3. Schiaffino S et al.. 2013. Mechanisms regulating skeletal muscle growth and atrophy.. FEBS J 280(17):4294-314 PMID: 23517348
- 4. McPherron AC et al.. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.. Nature 387(6628):83-90 PMID: 9139826
- 5. Tipton KD et al.. 2001. Exercise, protein metabolism, and muscle growth.. Int J Sport Nutr Exerc Metab 11(1):109-32 PMID: 11255140
- 6. Rogeri PS et al.. 2021. Strategies to Prevent Sarcopenia in the Aging Process: Role of Protein Intake and Exercise.. Nutrients 14(1) PMID: 35010928
- 7. Wang J et al.. 2018. Effects of microRNAs on skeletal muscle development.. Gene 668:107-113 PMID: 29775754
- 8. Lee SJ. 2004. Regulation of muscle mass by myostatin.. Annu Rev Cell Dev Biol 20:61-86 PMID: 15473835
